CD8A and neoplasm: Cell line and xenograft studies in other tumour types have demonstrated increased PD-L1 expression of tumour cells when treated with decitabine, resulting in improved recruitment CD8-positive T cells and enhanced the efficacy of immunotherapy targeting PD-L1 [82,84,85].